Prognosis method of cancer
AssigneesCentre National De La Recherche Scientifique, Centre Leon Berard, Institut National de la Sante et de la Recherche Medicale, Universite Claude Bernard Lyon 1
InventorsVéronique Maguer-Satta, Boris Guyot, Flora Clément, Pierre Saintigny, Jean-Philippe Foy, Emmanuel Delay
Life of this patent
Estimating the term…
Abstract
A method of prognosis of patient outcome and of the resistance to a chemotherapy treatment of an individual afflicted by a tumor. The method involves determining the amount of the product of each of at least 21 genes belonging to the group of 160 genes as set forth in SEQ ID NO: 1 to SEQ ID NO: 160.
Claims1
A composition consisting of pairs of oligonucleotides allowing the detection of at least 21 genes belonging to the group of 160 genes as set forth in SEQ ID NO:
- 1 to SEQ ID NO:
- 160, said at least 21 genes being the genes of the group consisting of the genes as set forth in SEQ ID NO:
- 7, SEQ ID NO:
- 11, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 20, SEQ ID NO:
- 22, SEQ ID NO:
- 28, SEQ ID NO:
- 30, SEQ ID NO:
- 34, SEQ ID NO:
- 40, SEQ ID NO:
- 54, SEQ ID NO:
- 72, SEQ ID NO:
- 74, SEQ ID NO:
- 76, SEQ ID NO:
- 100, SEQ ID NO:
- 102, SEQ ID NO:
- 127, SEQ ID NO:
- 141, SEQ ID NO:
- 149, SEQ ID NO:
- 150 and SEQ ID NO:
- 160,
- wherein the pairs of oligonucleotides are attached to a microarray.
Dependencies are inferred from the claim text.